Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc. (PLX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Protalix is a commercial-stage biopharmaceutical company utilizing its proprietary ProCellEx plant cell-based protein expression system. The company focuses on rare diseases, currently commercializing two enzyme replacement therapies (ERTs): Elelyso (for Gaucher disease) and Elfabrio (for Fabry disease). It is also advancing a pipeline including PRX-115 (for uncontrolled gout) and PRX-119 (for NETs-related diseases).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Total Revenue | $52.7 million | $53.4 million |
| Net Income (Loss) | $(6.6) million | $2.9 million |
| Operating Income (Loss) | $(5.5) million | $3.9 million |
| Research & Development Expenses | $19.6 million | $13.0 million |
| Cash and Cash Equivalents | $14.7 million | $19.8 million |
| Short-term Bank Deposits | $15.6 million | $15.1 million |
| Total Liquidity (Cash + Deposits) | $30.3 million | $34.9 million |
| Long-term Debt | $0 | $0 |
Note: The company repaid all outstanding convertible notes in September 2024. As of Dec 31, 2025, there is no long-term debt.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased slightly by 1.2% to $52.7 million. This was driven by a 23% decrease in sales to Chiesi (Elfabrio) due to inventory dynamics and pricing changes, partially offset by a 44% increase in sales to Pfizer (Elelyso) due to Pfizer's manufacturing needs.
- Net Loss: The company reported a net loss of $6.6 million in 2025, a reversal from the $2.9 million net income in 2024. This shift was primarily caused by a 51% increase in R&D expenses ($19.6M vs $13.0M) related to the Phase 2 RELEASE study for PRX-115.
- Operating Cash Flow: Net cash used in operating activities was $12.0 million in 2025, compared to $8.7 million provided in 2024. The outflow was driven by increased inventory levels ($4.5M increase) and accounts receivable ($5.9M increase).
- Regulatory Milestone: In March 2026 (subsequent to year-end), the European Commission approved a new 2 mg/kg every-4-weeks dosing regimen for Elfabrio, triggering a $25.0 million regulatory milestone payment from Chiesi.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash and short-term deposits ($30.3 million) are sufficient to fund operations for at least 12 months from the filing date.
- Pipeline Progress: The company is actively recruiting for the Phase 2 RELEASE study of PRX-115 (gout). The Phase 1 study was completed with positive safety and efficacy signals.
- Commercialization Risks: Revenue recognition is tied to bulk orders from partners (Chiesi, Pfizer, Fiocruz) rather than direct patient demand, leading to period-to-period volatility. Fiocruz (Brazil) has historically missed purchase milestones, creating uncertainty for that revenue stream.
- Geopolitical Risk: Operations are based in Israel. The filing highlights risks related to regional conflicts (Israel, Iran, Hamas, Hezbollah), though the company states operations have not been materially adversely affected as of the filing date. Drug substance is stored in multiple locations to mitigate risk.
- Intellectual Property: The company holds approximately 70 patents globally with 45 pending applications. Patents for Elelyso are expiring in various jurisdictions, while Elfabrio patents extend into the 2030s.
Investor Verification Checklist
- Chiesi Milestone Payment: Verify the receipt and timing of the $25.0 million regulatory milestone payment from Chiesi following the March 2026 EC approval of the E4W dosing regimen.
- PRX-115 Clinical Data: Monitor enrollment progress and interim data releases from the Phase 2 RELEASE study for uncontrolled gout.
- Fiocruz Compliance: Assess the status of the Brazil Agreement and whether Fiocruz has met purchase obligations, as this impacts the stability of the Elelyso revenue stream in Brazil.
- Inventory Levels: Review future inventory build-up for Elfabrio and Elelyso, as significant increases in inventory (as seen in 2025) can negatively impact operating cash flow.
- Geopolitical Impact: Monitor ongoing regional conflicts in the Middle East for potential disruptions to the manufacturing facility in Carmiel, Israel, or supply chain logistics.